



(12) **DEMANDE DE BREVET CANADIEN**
CANADIAN PATENT APPLICATION

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2019/04/17
(87) Date publication PCT/PCT Publication Date: 2020/08/27
(85) Entrée phase nationale/National Entry: 2020/12/08
(86) N° demande PCT/PCT Application No.: US 2019/027783
(87) N° publication PCT/PCT Publication No.: 2020/171833
(30) Priorité/Priority: 2019/02/22 (IN201941006993)

(51) CI.Int./Int.Cl. *A61K 36/185* (2006.01),
A61K 35/68 (2006.01), *A61K 36/81* (2006.01)

(71) Demandeur/Applicant:
SAMI LABS LIMITED, IN

(72) Inventeurs/Inventors:
MAJEED, MUHAMMED, IN;
NAGABHUSHANAM, KALYANAM, US;
BANI, SARANG, IN;
PANDEY, ANJALI, IN

(74) Agent: NORTON ROSE FULBRIGHT CANADA
LLP/S.E.N.C.R.L., S.R.L.

(54) Titre : COMPOSITION APHRODISIAQUE ET GESTION D'UN DYSFONCTIONNEMENT SEXUEL MALE
(54) Title: APHRODISIAC COMPOSITION AND MANAGEMENT OF MALE SEXUAL DYSFUNCTION

(57) Abrégé/Abstract:

The present invention discloses a composition for the therapeutic management of male sexual dysfunction and related disorders. Specifically, the invention discloses a composition comprising 60-65% w/w *Withania somnifera* extract, 12-18% w/w *Mucuna pruriens* extract, 5- 10% w/w *Coleus forskolii* extract, 12-18% w/w *Kaempferia parviflora* extract, 0.1 - 2% w/w *Piper nigrum* extract, for use as an aphrodisiac.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)**(19) World Intellectual Property Organization**

International Bureau

**(10) International Publication Number****WO 2020/171833 A1****(43) International Publication Date**

27 August 2020 (27.08.2020)

(51) International Patent Classification:

A61K 36/185 (2006.01) *A61K 36/81* (2006.01)
A61K 35/68 (2006.01)

Declarations under Rule 4.17:— *of inventorship (Rule 4.17(iv))***Published:**— *with international search report (Art. 21(3))***(21) International Application Number:**

PCT/US2019/027783

(22) International Filing Date:

17 April 2019 (17.04.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201941006993 22 February 2019 (22.02.2019) IN

(72) Inventors; and

(71) Applicants: **MAJEEED, Muhammed** [US/IN]; Sami Labs, Limited, 19/1 and 19/2, I Main, II Phase, Peenya Industrial Area, Bangalore, Karnataka 560058 (IN). **NAGABHUSHANAM, Kalyanam** [US/US]; Sabinsa Corporation, 20 Lake Drive, East Windsor, NJ 08520 (US). **BANI, Sarang** [IN/IN]; Sami Labs Limited, 19/1 and 19/2, I Main, II Phase, Peenya Industrial Area, Bangalore, Karnataka 560058 (IN). **PANDEY, Anjali** [IN/IN]; Sami Labs Limited, 19/1 and 19/2, I Main, II Phase, Peenya Industrial Area, Bangalore, Karnataka 560058 (IN).

(74) Common Representative: **NAGABHUSHANAM, Kalyanam**; Sabinsa Corporation, 20 Lake Drive, East Windsor, NJ 08520 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: APHRODISIAC COMPOSITION AND MANAGEMENT OF MALE SEXUAL DYSFUNCTION

(57) Abstract: The present invention discloses a composition for the therapeutic management of male sexual dysfunction and related disorders. Specifically, the invention discloses a composition comprising 60-65% w/w *Withania somnifera* extract, 12-18% w/w *Mucuna pruriens* extract, 5- 10% w/w *Coleus forskolii* extract, 12-18% w/w *Kaempferia parviflora* extract, 0.1 - 2% w/w *Piper nigrum* extract, for use as an aphrodisiac.

WO 2020/171833 A1

APHRODISIAC COMPOSITION AND MANAGEMENT OF MALE SEXUAL DYSFUNCTION

CROSS REFERENCE TO RELATED APPLICATIONS

This is a conventional application claiming priority from Indian patent application number IN201941006993 filed on February 22, 2019.

FIELD OF INVENTION

[Para 001] The present invention pertains to compositions for the therapeutic management of male sexual dysfunction and associated disorders. Specifically, the invention relates to compositions comprising plant extracts and phytochemical for the management of disorders related to male sexual dysfunction.

BACKGROUND OF THE INVENTION

[Para 002] Male sexual arousal is triggered by complex biochemical pathways, physical and psychological events that involve the nervous and vascular systems which include the brain, neurotransmitters, secondary messengers, smooth muscles, blood vessels etc. Sexual dysfunction occurs if the pathways involving any of the above are disturbed. The common types of male sexual dysfunction include erectile dysfunction, premature ejaculation, delayed or inhibited ejaculation, and reduced libido.

[Para 003] A combination of physical and physiological issues can cause sexual dysfunction in males, particularly erectile dysfunction. The brain plays a key role in triggering the series of physical events that cause an erection, starting with feeling of sexual excitement. Depression, anxiety or other mental health conditions, stress or relationship problems due to stress, poor communication causes or worsens erectile dysfunction.

[Para 004] State of the art explains penile erection is a complex process involving psychogenic and hormonal functionality and a neurovascular non adrenergic, non cholinergic mechanism. Nitrous oxide, produced by Corpora cavernosa is the main vasoactive noncholinergic and non adrenergic neurotransmitter and chemical mediator of erectile function. Nitric oxide stimulates the enzyme guanylate cyclase that converts GTP to 3', 5'-

cyclic guanosine monophosphate (cGMP). cGMP causes smooth muscles in the arteries to relax which increases the blood flow to the penis. The veins that carry blood away from the penis constrict, thus trapping the pressurized blood in the Corpora cavernosa resulting in the erection.

[Para 005] Moreover, the cGMP level plays major role in maintaining the erection for longer time. Ideally the cGMP is converted into 5' GMP by phospho diesterase enzyme, thus reducing the erection. Inhibition of Phospho diesterase enzyme can prolong the erection of the penis providing sexual satisfaction (Please provide reference)

[Para 006] Hence for treatment of penile dysfunction and therapeutic management of associated male sexual dysfunctions it is necessary to target every stage of mechanism wherein level of nitric oxide are increased increasing the penile blood flow, activation of enzyme guanylate cyclase to increase the levels of cyclic monophosphate (cGMP), and increased levels of cGP specific protein kinase to increase smooth muscle relaxation.

[Para 007] State of the art chemical compositions includes one or more agents that act through various routes in treatment of male sexual dysfunction. Few prior arts are mentioned below:

[Para 008] Wipo application number WO2018220232 explains composition comprising botulinum toxin mainly onabotulinum toxin A, abobotulinumtoxin A and incobotulinumtoxin A; PDE5 inhibitors mainly sildenafil citrate, Iodenafil, avanafil, mirodenafil, sildeafil, tadalafil and other derivatives for simultaneous, sequential or separate use in the treatment of erectile functions.

[Para 009] US application number 15/434226 titled Composition and method for treatment of erectile dysfunction disclosed use of one chemically active anti erectile dysfunction drug (AED) like vaedenafil, avanafil and its acceptable salts along with cannabis and its extract in combination.

[Para 0010] US patent number 7,147,874 discloses pharmaceutical composition for the prevention and treatment of premature ejaculation and/or hypersensitivity of sexual stimulation are provided. The composition contains purified sumsoo extract and purified

ginseng extract containing saponin as the main component, without other herbal essential oil components.

[Para 0011] US 2006/0269623 teaches about herbal compositions and methods of treatment for prevention or treatment of erectile dysfunction disorders and ameliorating symptoms thereof and as a preventative measure against erectile dysfunction. The methods comprise administering a therapeutically effective composition of matter comprising the following herbal and other components: Herba cynomorii, Rhizomnas atractylodis macrocephalae, Radix rehmannia glutinosea longui, Herba epimedii, Fructus lycii, Fructus schisandrae chinensis, Radix poloygoni multiflor, Cortex cinnamonia cassiae, Fructus amoni, and Radix ginseng. Kotta et al., (Kotta et al., Exploring scientifically proven herbal aphrodisiacs, Pharmacogn Rev. 2013 Jan-Jun; 7(13): 1-10) reviews about the different herbal aphrodisiacs used in the Ayurvedic system of medicine.

[Para 0012] Various other devices such as vacuum devices, penile implants are available, but benefit only those patients whose function has been severely impaired. It has been observed that bruising, skin breakdown, and penile pain may occur while using these devices.

[Para 0013] The existing treatments for male sexual dysfunction do not target all the aspects of sexual dysfunction leading to relapse of the condition. Moreover they are reported to have side effects or are not very comfortable for usage. Hence, there is an unmet industrial need to provide a product which is safe and efficient in therapeutic management of male sexual dysfunction by targeting the complete pathophysiological aspects of Sexual Dysfunction.

[Para 0014] The present invention solves the above problem by disclosing a composition comprising plant extracts and phytochemical for use as an aphrodisiac and in the therapeutic management of male sexual dysfunction and related disorders.

[Para 0015] It is the principle object of the invention to disclose a composition comprising 60-65% w/w *Withania somnifera* extract standardized to contain 0.25% withaferin and 7% withanolides, 12-18% w/w *Mucuna pruriens* extract standardized to contain 10% w/w L-dopa, 5-10% w/w *Coleus forskohlii* extract standardized to contain 10% w/w forskolin, 12-18% w/w *Kaempferia parviflora* standardized to contain 2.5% w/w of 5,7-dimethoxyflavone

and not less than 10% w/w Total fand 0.1 – 2% w/w Piper nigrum extract standardized to contain 95% w/w Piperine for use as an aphrodisiac.

[Para 0016] It is another object of the invention to disclose a method for the therapeutic management of male sexual dysfunction and related disorders using a composition comprising 60-65% w/w Withania somnifera extract standardized to contain 0.25% withaferin and 7% withanolides, 12-18% w/w Mucana pruriens extract standardized to contain 10% w/w L-dopa, 5-10% w/w Coleus forskohlii extract standardized to contain 10% w/w forskolin, 12-18% w/w Kaempferia parviflora standardized to contain 2.5% w/w of 5,7-dimethoxyflavone and not less than 10% w/w Total flavonoids and 0.1 – 2% w/w Piper nigrum extract standardized to contain 95% w/w Piperine.

[Para 0017] The present invention solves the above objectives and provides further related advantages.

SUMMARY OF THE INVENTION

[Para 0018] The present invention provides a composition for the therapeutic management of male sexual dysfunction and related disorders.

[Para 0019] More specifically, the invention discloses a composition comprising 60-65% w/w Withania somnifera extract standardized to contain 0.25% withaferin and 7% withanolides, 12-18% w/w Mucana pruriens extract standardized to contain 10% w/w L-dopa, 5-10% w/w Coleus forskohlii extract standardized to contain 10% w/w forskolin, 12-18% w/w Kaempferia parviflora standardized to contain 2.5% w/w of 5,7-dimethoxyflavone and not less than 10% w/w Total flavonoids and 0.1 – 2% w/w Piper nigrum extract standardized to contain 95% w/w Piperine for use as an aphrodisiac by increasing the levels of nitric oxide, testosterone and cGMP.

[Para 0020] Other features and advantages of the present invention will become apparent from the following more detailed description, taken in conjunction with the accompanying images, which illustrate, by way of example, the principle of the invention.

BRIEF DESCRIPTION OF DRAWINGS

[Para 0021] **Fig. 1** is a graphical representation showing the effect of the formulation on mounting behavior in male wistar rats (long term effect).

[Para 0022] **Fig. 2** is a graphical representation of serum testosterone levels in male wistar rats administered with different concentrations of the formulation.

[Para 0023] **Fig. 3** is a graphical representation showing the serum androstenedione levels in male wistar rats administered with different concentrations of the formulation.

[Para 0024] **Fig. 4** is a graphical representation showing the levels of serum cGMP in male wistar rats administered with different concentrations of the formulation.

[Para 0025] **Fig. 5** is a graphical representation showing the levels of serum cGMP specific kinase in male wistar rats administered with different concentrations of the formulation.

[Para 0026] **Fig. 6** is a graphical representation showing the comparative evaluation of the effect of formulation and individual plant actives on the levels of serum cGMP in male wistar rats

[Para 0027] **Fig. 7** is a graphical representation showing the comparative evaluation of the effect of formulation and individual plant actives on the levels of serum cGMP specific kinase in male wistar rats.

DESCRIPTION OF PREFERRED EMBODIMENTS

[Para 0028] The invention is described in detail with each preferred embodiment for better understanding and to enable a person moderately skilled in the art to manifest or practice the invention.

[Para 0029] In the most preferred embodiment the present invention discloses a composition comprising 60-65% w/w *Withania somnifera* extract, 12-18% w/w *Mucuna pruriens* extract, 5-10% w/w *Coleus forskohlii* extract, 12-18% w/w *Kaempferia parviflora* extract and 0.1 – 2% w/w *Piper nigrum* extract. In a related aspect, the composition comprises at least one phytochemical selected from the group of phospho diesterase 5 (PDE-5) inhibitor;

testosterone enhancer, Nitric oxide enhancer, cGMP enhancer, anti-spasmodic and vasodilator, androgen receptor activator and cGMP protein kinase activator.

[Para 0030] In a related aspect, the *Withania somnifera* extract is standardized to contain 0.25% withaferin and 7% withanolides. In another related aspect, the *Mucana pruriens* extract is standardized to contain 10% w/w L-dopa. In yet another related aspect, the *Coleus forskohlii* extract is standardized to contain 10% w/w forskolin. In another related aspect, the *Kaempferia parviflora* extract is standardized to contain 2.5% w/w of 5,7-dimethoxyflavone and not less than 10% w/w Total flavonoids.

[Para 0031] In another preferred embodiment, the invention discloses a composition comprising 60-65% w/w *Withania somnifera* extract standardized to contain 0.25% withaferin and 7% withanolides, 12-18% w/w *Mucana pruriens* extract standardized to contain 10% w/w L-dopa, 5-10% w/w *Coleus forskohlii* extract standardized to contain 10% w/w forskolin, 12-18% w/w *Kaempferia parviflora* standardized to contain 2.5% w/w of 5,7-dimethoxyflavone and not less than 10% w/w Total flavonoids and 0.1 – 2% w/w *Piper nigrum* extract standardized to contain 95% w/w Piperine for use as an aphrodisiac.

[Para 0032] In a related aspect, the composition comprises at least one phytochemical selected from the group of phospho diesterase 5 (PDE-5) inhibitor; testosterone enhancer, Nitric oxide enhancer, cGMP enhancer, anti-spasmodic and vasodilator, androgen receptor activator and cGMP protein kinase activator. In another related aspect, the composition is formulated with pharmaceutically/nutraceutically acceptable excipients, adjuvant, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewable, candies or eatables.

[Para 0033] In another preferred embodiment, the invention discloses a method for increasing libido in mammals, said method comprising step of administering an effective dose of a composition, based on the body weight of the mammal, comprising 60-65% w/w *Withania somnifera* extract standardized to contain 0.25% withaferin and 7% withanolides, 12-18% w/w *Mucana pruriens* extract standardized to contain 10% w/w L-dopa, 5-10% w/w *Coleus forskohlii* extract standardized to contain 10% w/w forskolin, 12-18% w/w *Kaempferia parviflora* standardized to contain 2.5% w/w of 5,7-dimethoxyflavone and not less than 10%

w/w Total flavonoids and 0.1 – 2% w/w Piper nigrum extract standardized to contain 95% w/w Piperine to mammals in need of such effect. In a related aspect, the composition comprises at least one phytochemical selected from the group of phospho diesterase 5 (PDE-5) inhibitor; testosterone enhancer, Nitric oxide enhancer, cGMP enhancer, anti-spasmodic and vasodilator, androgen receptor activator and cGMP protein kinase activator. In a related aspect, the effect dose of the composition is 50-200 mg/kg body weight. In another related aspect, the mammal is preferably male. In another related aspect, the mammal is preferably human. In another related aspect, the composition is formulated with pharmaceutically/nutraceutically acceptable excipients, adjuvant, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewable, candies or eatables.

[Para 0034] In yet another preferred embodiment, the invention discloses a method for therapeutic management of male sexual dysfunction and related disorders in mammals, said method comprising step of administering an effective dose of a composition, based on the body weight of the mammal, comprising 60-65% w/w Withania somnifera extract standardized to contain 0.25% withaferin and 7% withanolides, 12-18% w/w Mucuna pruriens extract standardized to contain 10% w/w L-dopa, 5-10% w/w Coleus forskohlii extract standardized to contain 10% w/w forskolin, 12-18% w/w Kaempferia parviflora standardized to contain 2.5% w/w of 5,7-dimethoxyflavone and not less than 10% w/w Total flavonoids and 0.1 – 2% w/w Piper nigrum extract standardized to contain 95% w/w Piperine to mammals in need of such effect. In a related aspect, the male sexual dysfunction is selected from the group comprising erectile dysfunction, premature ejaculation, Delayed or inhibited ejaculation, and reduced libido. In a related embodiment, the male sexual dysfunction is preferably erectile dysfunction and reduced libido. In a related aspect, the management of male sexual dysfunction is brought about by inhibiting phospho diesterase 5 (PDE-5), enhancing testosterone, Nitric oxide and cGMP levels and activating androgen receptor and cGMP protein kinase. In a related aspect, the effect dose of the composition is 50-200 mg/kg body weight. In another related aspect, the mammal is preferably male. In another related aspect, the mammal is preferably human. In another related aspect, the composition is formulated with pharmaceutically/nutraceutically acceptable excipients,

adjuvant, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewable, candies or eatables.

[Para 0035] Specific illustrative examples enunciating the most preferred embodiments are included herein below.

[Para 0036] Examples

[Para 0037] Example 1: Details of the composition

[Para 0038] The present invention discloses a synergistic composition comprising 60-65% w/w *Withania somnifera* extract, 12-18% w/w *Mucana pruriens* extract, 5-10% w/w *Coleus forskohlii* extract, 12-18% w/w *Kaempferia parviflora* extract and 0.1 – 2% w/w *Piper nigrum* extract. The details and the intended therapeutic potential in the management of male sexual dysfunction of the individual plant extracts are provided below:

[Para 0039] *Withania somnifera* commonly known as ashwagandha, Indian ginseng, poison gooseberry or winter cherry is a plant in the Solanaceae family. Synonyms for *Withania somnifera* are *Physalis somnifera* L., *Withania kansuensis* Kuang & A. M. Lu and *Withania microphysalis*. The main phytochemical component constitutes withanolides which are triterpene lactones mainly withanolides, withaferin A, alkaloids, steroidal lactones, tropine and cuscohygrine. (Ashwagandha". Drugs.com. 2009. Retrieved 27 December 2018). The alkaloids of *Withania somnifera* are reported to increase production of nitric oxide and improve vascular endothelial abnormalities. The sterols present in the extract stimulate sexual and adrenal functions (Kumar et.al., Chemistry and pharmacology of *withania somnifera*: An update, TANG Humanitas Medicine, 2015; 5(1):1-13) and flavonoids aids in the protections of cardiovascular system. (Narinderpal et.al.,A Review on Pharmacological Profile of *Withania somnifera* (Ashwagandha), Research & Reviews: Journal of Botanical Sciences, 2013; 2(4); 1-9)

[Para 0040] *Mucana pruriens* commonly known as velvet bean, Bengal velvet bean, Florida velvet bean, Mauritius velvet bean, yokohama velvet bean, cowage co witch, lacuna bean and Lyon bean. It is a tropical legume native to Africa and tropical Asia and widely naturalizes and cultivated. The seeds of the plant contain L-Dopa, with trace amount of serotonin,

nicotine and bufotenine. The plant and its extracts have been long used in tribal communities as a toxin antagonist for various snakebites. It has also been used in traditional ayurveda Indian medicine to treat diseases including Parkinson's disease (Cilia et. al., Mucuna Pruriens in Parkinson disease, Neurology, 2017 Aug 1; 89(5): 432–438). Levodopa or L-dopa present in the seed of the plant is vital for the synthesis of dopamine, a neurotransmitter that plays a important function in sexual arousal. L-dopa helps to prolong time of intercourse and is reported to address the symptoms of premature ejaculation. (Morales et. al. Evolving therapeutic strategies for premature ejaculation: The search for on-demand treatment – topical versus systemic, Canadian Urological Association Journal, 2012; 6(5) 380-385)

[Para 0041] *Piper nigrum* is a flowering vine in the family Piperaceae, cultivated for its fruit, which is usually dried and used as a spice and seasoning agent, the fruit contains many terpenes, including germacrene, limoline, pipene and alpha- phellandrene and beta-caryophyllene. (Pund et. al. Nanoarchitectures for Neglected Tropical Protozoal Diseases: Challenges and State of the Art, Science Direct, 2016) Black pepper is also reported to contain Piperine which is used as a bioavailability enhancer. (Kesarwani et. al. Bioavailability enhancers of herbal origin: An overview, Asia Pacific Journal of Topical Biomedicine, 2013; 3(4) 253-266). Piperine is also reported to increase the levels of CoQ10 in the blood which triggers blood flow to the entire body including penile vein.

[Para 0042] *Coleus forskohlii* also known as Plectranthus barbatus is a tropical perennial plant related to the typical coleus species. It produces forskolin, an extract useful for pharmaceutical preparations. In ayurveda, *Coleus* is used to treat heart disease, spasmotic pain, painful urination and convulsions (Meghwal et. al. Nutritional Constituent of Black pepper as Medicinal Modules: A Review. Open Access Scientific Reports, 2012, 1(1) 1-7). Forskolin is reported to increase cAMP, androgen receptor activity and promote steroidogenesis. Forskolin also increases androgen receptor sensitivity thereby increasing the utilization of testosterone (Neto et. al. Vasodilation induced by forskolin involves cyclic GMP production. Journal of Biophysical Chemistry, 2011 2(4), 1-7)

[Para 0043] *Kaempferia parviflora* also known as Thai black ginger, Thai ginseng or krachai dum, is an herbaceous plant in the family Zingiberaceae. *K. parviflora* has pharmacological

activities such as anti-inflammatory, antioxidant, and aphrodisiac, anti gastric ulcer effect, antiplasmodial, antifungal, and antibacterial activities. *K. parviflora* is reported to contain many flavonoids which is responsible for its therapeutic potential. The plant is known for its PDE5 inhibition and activation of cGMP protein kinase which in turn decrease the concentration of Ca⁺ and accelerates smooth muscles relaxation in the penile smooth muscles (Chen et.al. Kaempferia parviflora and its methoxyflavone: Chemistry and Biological Activities. Evidence-Based Complementary and Alternative Medicine; 2018; Article ID 4057456, 1-15)

[Para 0044] The composition disclosed in the invention targets all the mechanisms of male fertility and provides synergistic effects. The constituent of the composition is mentioned in **table 1**.

[Para 0045] Table 1; Composition details

Extract	Dose (mg/kg body weight)
Withania somnifera	400
Mucana pruriens	100
Coleus forskohlii	50
Kaempferia parviflora	100
Piper nigrum	5

[Para 0046] Example 2: Reproductive performance study

[Para 0047] The invention composition was experimented in male wistar rats and observed for the reproductive performance studies. Both behavioral and biochemical assessments were

carried out and the findings that support the claimed invention is described with examples in the detailed description of the invention.

[Para 0048] Behavioral assessment

[Para 0049] Mounting behavior:

Treatment	Dose (mg/kg)	No. of mounts per 15 minutes				Averag increas (%)
		Mean \pm SE				
		0	7	14	21	
Control	-	1.50 \pm 0.22	1.33 \pm 0.21	1.33 \pm 0.21	1.50 \pm 0.22	
Formulation	50	4.00 \pm 0.25 (167)	3.16 \pm 0.30 (138)	3.33 \pm 0.2 (150)	3.66 \pm 0.21 (144)	149.75
Formulation	100	5.00 \pm 0.25 (233.3)	5.33 \pm 0.60 (300)	4.33 \pm 0.21(225)	4.83 \pm 0.40 (222)	245.07
Formulation	200	5.50 \pm 0.34 (267)	5.00 \pm 0.60 (275.9)	4.66 \pm 0.21 (250.3)	5.00 \pm 0.25 (233)	256.5

[Para 0050] Non- estrous female rats were paired with males treated with single dose of the formulation. Animals were observed for 3h (acute effect) for their sexual behavior (Tajuddin et. al., Aphrodisiac activity of 50% ethanol extracts of *Myristica fragrans* Houtt. (Nutmeg) and *Syzygium aromaticum* (L.) Merr. & Perry. (Clove) in male mice: a comparative study. BMC Complement Altern Med. 2003;3:6.). Number of mounts along with other courtship activities recorded during 15 min observation period at the start of 1st hour. Female separated for 105 minutes. Again introduced and number of mounts observed for 15 minutes (3rd h). The results are tabulated in **Table 2 and Fig. 1**.

[Para 0051] Table 2: Effect of Formulation on mounting behavior in male wistar rats (Long term effect)

[Para 0052] Values in parenthesis show percentage increase against control

[Para 0053] The formulation significantly increased the number of mounts indicating that it is a very effective aphrodisiac.

[Para 0054] Assessment of mating:

[Para 0055] After 1 hour of drug administration to a single male, five estrus females admitted into cage and kept as such overnight. Vaginal smear of each female rat examined microscopically for the presence of sperms the next morning. The stage of the estrous cycle was determined according to the criteria laid down by Dewsbury DA et. al., Effect of reserpine on the copulatory behaviour of Male rats. *Physiol Behav*. 1970;5:1331–1333; Szechtman H, Moshe H, et.al. Sexual behaviour Pain sensitivity and stimulates endogenous opioid in male rats. *Eur J Pharmacol*. 1981;70:279–285. The results are tabulated as **table 3**

Table 3: Effect of Formulation on mating performance in male wistar rats

Treatment	Dose (mg/kg)	Number of pregnant females
		(5 females with a single male overnight) mean±S.E.
Control	-	1.33±0.33
Formulation	50	2.16±0.16 (62)
Formulation	100	2.50±0.33 (88)
Formulation	200	2.66±0.33 (100)

[Para 0056] Values in parenthesis show percentage increase against control

[Para 0057] The results indicated an increase in mating performance of male rats administered with the formulation.

[Para 0058] Observation of Coolidge effect of formulation in male wistar rat

[Para 0059] The Coolidge effect is a phenomenon wherein males exhibit renewed sexual interest when a new female is introduced, even after cessation of sex with prior but still available sexual partners. The effect in male wistar rats was determined by the procedures laid down by Reber, A. S. & Reber, E., The Penguin dictionary of psychology (3rd ed.), London: Penguin; Brown, R. E. (1974), "Sexual arousal, the Coolidge effect and dominance in the rat (*Rattus norvegicus*)", *Animal Behaviour*, 22 (3): 634–637; Lester, GL; Gorzalka, BB (1988), "Effect of novel and familiar mating partners on the duration of sexual receptivity in the female hamster", *Behavioral Neural Biology*, 49 (3): 398–405; Pinel, John (2007), *Biopsychology* (6th ed.), Boston: Pearson Allyn and BaconAfter 6 hours of drug treatment all the females were replaced with the fresh estrous female for next 6 hours.

[Para 0060] Vaginal smears of all the females observed microscopically to confirm intromission and ejaculation in the first set and also in the second set of females to confirm the Coolidge effect. **Table 4** indicates the percentage increase in no. of female pregnant rates against control samples and between first set of females and the replaced set.

Table 4: Coolidge effect of Formulation in male wistar rats

Treatment	Dose (mg/g)	Number of pregnant females/ male rat	
		1 st 6 hr (mean±S.E.)	2 nd 6 hr (mean±S.E.)
Control	-	1.66±0.33	1.0±0.22
Formulation	50	2.16±0.30 (30.12)	1.33±0.49 (33)

Formulation	100	2.50±0.22 (50.60)	1.45±0.16 (45)
Formulation	200	2.83±0.54 [Para 0061](70.48)	1.66±0.42 [Para 0062](66)

[Para 0063] Values in parenthesis show percentage increase against control

[Para 0064] Electric barrier effect on sexual behavior

[Para 0065] The experimental procedures to observe electric barrier effect on sexual behavior were carried out as set forth by Graham JH et. al., Inhibitory avoidance behavior and memory assessment 2001. In Buccafusco JJ (ed.), methods of Behavior analysis in Neuroscience, p.141-151. Boca Raton: CRC Press. In this experiment the receptive (oestrous) female was kept on one side of the cage and test sample treated male rat on the other side of the same cage. In between was an electric barrier. Foot-shocks were delivered through grids present in the floor. Observations were recorded for both treated as well as the control groups with respect to the inclination of male rat to cross the barrier. The results are tabulated as **table 5**

Table 5: Effect of Formulation on electric barrier function

Treatment	Dose (mg/kg)	Number of males that crossed the electric barrier/ Total number of treated male rats
Control	-	0/6
Formulation	50	1/6
Formulation	100	3/6
Formulation	200	3/6

[Para 0066] Biochemical Assessment

[Para 0067] Estimation of Testosterone

[Para 0068] Testosterone is the principal male hormone produced by the interstitial (Leydig) cells of the male testes and in smaller amounts by the adrenals . Testosterone in males is responsible for maintenance of reproductive system and secondary sexual characters throughout the life of the male. The treated groups were given the formulation and levels were measured after 1hr and 3 hr as per standard protocol.

[Para 0069] The data shows increase in testosterone concentration in serum of treated animals after 1hr and 3hr (**Fig. 2**). **Table 6** shows the Percentage activity of testosterone against control over a period of 21 days.

Table 6: Percentage activity of testosterone against control (Day 1-Day21)

Treatment	Dose (mg/kg)	Percentage increase of testosterone after 1hr of administration of the formulation			
		1 st day	7 th day	14 th day	21 st day
Control	-	-	-	-	-
Formulation	50	11.49	14.58	17.47	23.96
Formulation	100	14.60	18.75	19.05	24.17
Formulation	200	12.30	19.16	20.46	20.83

[Para 0070] The experimental animals had the same increase of testosterone throughout the use of formulation; it is a safe long-term solution for improved testosterone.

[Para 0071] Androstenedione estimation:

[Para 0072] Androstenedione is a steroid hormone that mainly acts as a stepping stone in the manufacture of testosterone and estrogen within the body. Males with too little androstenedione may fail to develop the sexual characteristics associated with puberty, including pubic and body hair, growth of the sexual organs and deepening of the voice. Androstenedione was estimated as per standard protocol.

[Para 0073] The results indicated an increase in androstenedione concentration in serum of treated animals after 1hr of administration of the formulation (**Fig. 3**). **Table 7** shows the Percentage activity of androstenedione against control over a period of 21 days.

Table 7: Percentage activity of androstenedione against control (Day 1-Day21)

Treatment	Dose (mg/kg)	Percentage increase of testosterone after 1hr of administration of the formulation			
		1 st day	7 th day	14 th day	21 st day
Control	-	-	-	-	-
Formulation	50	33.10	14.01	19.19	22.21
Formulation	100	24.94	21.01	25.19	21.77
Formulation	200	24.48	23.54	27.13	28.14

[Para 0074] Nitric Oxide estimation:

[Para 0075] The signal nitric oxide NO is released from nerve endings or from endothelial cells and activates a cascade reaction, which ultimately leads to an increased cellular concentration of cGMP (cyclic guanosine monophosphate). This second messenger molecule induces a series of events that lead to smooth-muscle relaxation through a reduction in the intracellular calcium ion concentration. The clinically important inhibitors (sildenafil, vardenafil and tadalafil) all act to promote smooth-muscle relaxation by their ability to allow cGMP to accumulate when nitric oxide is released, as is the case when sexual stimulation is present.

[Para 0076] Nitric oxide was estimated in the serum of male wistar rats by ELISA. The method employed is as per the procedure described by Miles et. al. Determination of nitric oxide using fluorescence spectroscopy. Methods Enzymol.1996; 268:105-20. The results indicated an increase in Nitric oxide concentration in serum of treated animals after 1hr of administration of the formulation (**Table 8**).

Table 8: Nitric oxide estimation in serum of male wistar rats by ELISA

Treatment	Dose (mg/kg)	Nitric oxide (μmole/l)
		Mean ± S.E.
Control	-	140.53±4.25
Formulation	50	147.12±8.16 (4.68)
Formulation	100	159.47±7.33 (13.48)
Formulation	200	165.33±12.33 (17.64)

[Para 0077] Values in parenthesis show percentage increase against control

[Para 0078] cGMP and cGMP specific protein kinase estimation

[Para 0079] The cGMP and cGMP specific protein kinase levels were also estimated in the serum of male wistar rats. The results indicated an increase in cGMP (**Fig. 4**) and cGMP-PK1 concentration (**Fig. 5**) in serum of treated animals after 1hr of administration of the formulation

[Para 0080] The comparative effect of Individual ingredients and Formulation on cGMP and cGMP specific protein kinase were evaluated. The results indicated a synergistic effect in cGMP concentration (**Fig. 6**) and cGMP-PK1 concentration (**Fig. 7**) in serum of treated animals after 1hr of administration of the test drugs when compared to the expression of cGMP in individual ingredient treated group.

[Para 0081] Example 3: Cardiovascular function study

[Para 0082] The objective of this study in rats was to determine the effect of the test material on cardiovascular system in experimental rats when administered intraduodenally. Formulation when administered to normotensive, anaesthetized, male Wistar rats intraduodenally with three different doses (50, 100 & 200 mg/kg) showed no effect (increase or decrease) on blood pressure, heart rate & respiration. The observations were taken up to three hours at one hour interval after the drug administration. In all the three parameters at graded doses no change has been observed at any interval of the time.

[Para 0083] The results are tabulated as Tables 9-11

Table 9: Effect of test drug on blood pressure in anaesthetized male rats

Dose	Blood Pressure (mmHg)			
	Initial	1 hour	2 hour	3 hour
Formulation 50 mg/kg	186.66±1.69	186.66±4.70	182.00±4.96	183.66±2.62
Formulation [Para 0084] 100 mg/kg	190.66±4.10	198.33±10.27	192.00±9.21	191.66±13.12
Formulation [Para 0085] 200 mg/kg	184.66±3.68	190.33±2.35	186.66±4.71	185.00±0.00

[Para 0086] The data showed no significant increase/ decrease on blood pressure in treated animals.

Table 10: Effect of test drug on respiration in anaesthetized male rats

Dose	Respiration rate (breaths / min.)				
	Initial	30 min	1 hour	2 hour	3 hour
Formulation 50 mg/kg	89.02±1.55	87.66±2.05	90.33±2.05	91.83±3.74	89.66±2.18
Formulation 100 mg/kg	92.33±5.43	91.45±4.21	92.84±2.35	88.76±2.81	90.23±3.57
Formulation 200 mg/kg	90.33±2.05	89.66±5.79	92.00±4.32	92.33±5.43	93.00±6.68

[Para 0087] The data showed no significant increase/ decrease on respiration rate in treated animals

[Para 0088] **Table 11: Effect of test drug on Heart rate in anaesthetized male rats**

Dose	Heart rate (beats / min.)			
	Initial	1 hour	2 hour	3 hour
Formulation 50 mg/kg	328.33±5.88	325.00±7.07	331.25±11.57	329.14±6.40
Formulation 100 mg/kg	333.33±6.23	336.66±4.71	328.64±11.11	331.31±9.65
Formulation 200 mg/kg	321.66±13.12	328.33±12.47	318.33±8.49	313.33±4.71

[Para 0089] The data showed no significant increase/ decrease on heart rate in treated animals

[Para 0090] The results indicated that the formulation is very safe and exhibited an excellent aphrodisiac potential useful for the management of male sexual dysfunction.

[Para 0091] Other modifications and variations to the invention will be apparent to those skilled in the art from the foregoing disclosure and teachings. Thus, while only certain embodiments of the invention have been specifically described herein, it will be apparent that numerous modifications may be made thereto without departing from the spirit and scope of the invention. The scope of the invention is to be interpreted only in conjunction with the appended claims.

We claim,

1. A composition comprising 60-65% w/w *Withania somnifera* extract standardized to contain 0.25% withaferin and 7% withanolides, 12-18% w/w *Mucuna pruriens* extract standardized to contain 10% w/w L-dopa, 5-10% w/w *Coleus forskolii* extract standardized to contain 10% w/w forskolin, 12-18% w/w *Kaempferia parviflora* standardized to contain 2.5% w/w of 5,7-dimethoxyflavone and not less than 10% w/w Total flavonoids and 0.1 – 2% w/w *Piper nigrum* extract standardized to contain 95% w/w piperine for use as an aphrodisiac.
2. The composition as in claim 1, wherein the composition comprises atleast one phytochemical selected from the group of phospho diesterase 5 (PDE-5) inhibitor; testosterone enhancer, Nitric oxide enhancer, cGMP enhancer, anti-spasmodic and vasodilator, androgen receptor activator and cGMP protein kinase activator.
3. The composition as in claim 1, wherein the composition is formulated with pharmaceutically/nutraceutically acceptable excipients, adjuvants, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewable, candies or eatables.
4. A method for increasing libido in mammals, said method comprising step of administering an effective dose of a composition, based on the body weight of the mammal, comprising 60-65% w/w *Withania somnifera* extract standardized to contain 0.25% withaferin and 7% withanolides, 12-18% w/w *Mucuna pruriens* extract standardized to contain 10% w/w L-dopa, 5-10% w/w *Coleus forskolii* extract standardized to contain 10% w/w forskolin, 12-18% w/w *Kaempferia parviflora* standardized to contain 2.5% w/w of 5,7-dimethoxyflavone and not less than 10% w/w Total flavonoids and 0.1 – 2% w/w *Piper nigrum* extract standardized to contain 95% w/w piperine to mammals in need of such effect.
5. The method as in claim 4, wherein the composition comprises atleast one phytochemical selected from the group of phospho diesterase 5 (PDE-5) inhibitor; testosterone

enhancer, Nitric oxide enhancer, cGMP enhancer, anti-spasmodic and vasodilator, androgen receptor activator and cGMP protein kinase activator.

6. The method as in claim 4, wherein the effect dose of the composition is 50-200 mg/kg body weight.
7. The method as in claim 4, wherein the mammal is preferably male.
8. The method as in claim 4, wherein the mammal is preferably human.
9. The method as in claim 4, wherein the composition is formulated with pharmaceutically/nutraceutically acceptable excipients, adjuvants, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewable, candies or eatables.
10. A method for therapeutic management of male sexual dysfunction and related disorders in mammals, said method comprising step of administering an effective dose of a composition, based on the body weight of the mammal, comprising 60-65% w/w *Withania somnifera* extract standardized to contain 0.25% withaferin and 7% withanolides, 12-18% w/w *Mucuna pruriens* extract standardized to contain 10% w/w L-dopa, 5-10% w/w *Coleus forskolii* extract standardized to contain 10% w/w forskolin, 12-18% w/w *Kaempferia parviflora* standardized to contain 2.5% w/w of 5,7-dimethoxyflavone and not less than 10% w/w Total flavonoids and 0.1 – 2% w/w *Piper nigrum* extract standardized to contain 95% w/w piperine to mammals in need of such effect.
11. The method as in claim 10, wherein the male sexual dysfunction is selected from the group comprising erectile dysfunction, premature ejaculation, delayed or inhibited ejaculation, and reduced libido.
12. The method as in claim 10, wherein the male sexual dysfunction is preferably erectile dysfunction and reduced libido.
13. The method as in claim 10, wherein the management of male sexual dysfunction is brought about by inhibiting phospho diesterase 5 (PDE-5), enhancing testosterone, Nitric oxide and cGMP levels and activating androgen receptor and cGMP protein kinase.

14. The method as in claim 10, wherein the effective dose of the composition is 50-200 mg/kg body weight.
15. The method as in claim 10, wherein the mammal is preferably male.
16. The method as in claim 10, wherein the mammal is preferably human.
17. The method as in claim 10, wherein the composition is formulated with pharmaceutically/nutraceutically acceptable excipients, adjuvants, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewable, candies or eatables.

Fig. 1




Fig 2




Fig 3




Fig 4




Fig 5




Fig 6




Fig 7

